Cannabis use and trauma were linked to psychotic symptoms in schizophrenia but not primary negative symptoms
Among 167 clozapine-treated schizophrenia patients, those with primary negative symptoms (deficit schizophrenia) had significantly lower rates of cannabis use and trauma exposure, suggesting these late-life insults drive psychotic rather than negative symptoms.
Quick Facts
What This Study Found
Deficit schizophrenia patients had significantly lower cannabis use at first psychotic episode (p=0.005), less physical/sexual abuse (p=0.033), and less crime-related trauma (p=0.012). Summer birth was associated with deficit schizophrenia (p=0.017). Family history, paternal age, sex, and birth weight did not differ.
Key Numbers
Patients: 167. Cannabis use lower in deficit group (p=0.005). Physical/sexual abuse lower in deficit (p=0.033). Crime-related trauma lower in deficit (p=0.012). Summer birth higher in deficit (p=0.017).
How They Did This
Cross-sectional single-center study of 167 clozapine-treated schizophrenia patients in England assessed with the Schedule for the Deficit Syndrome. Compared risk factors between deficit (primary negative symptoms) and nondeficit groups using logistic regression.
Why This Research Matters
Understanding that cannabis and trauma are linked specifically to psychotic symptoms rather than primary negative symptoms helps refine schizophrenia subtypes and may have implications for prevention targeting.
The Bigger Picture
The finding suggests schizophrenia with prominent negative symptoms may be driven more by early neurodevelopmental factors (summer birth), while cannabis and trauma act as later environmental triggers primarily for positive psychotic symptoms.
What This Study Doesn't Tell Us
Cross-sectional design. All patients on clozapine, limiting generalizability to treatment-resistant cases. Retrospective recall of risk factors. Single-center UK study.
Questions This Raises
- ?Could cannabis prevention reduce the burden of positive psychotic symptoms in schizophrenia while having less impact on negative symptoms?
- ?What about summer birth drives deficit schizophrenia?
Trust & Context
- Key Stat:
- Cannabis use significantly lower in deficit schizophrenia patients (p=0.005)
- Evidence Grade:
- Specialized clinical cohort with validated assessment tools, but cross-sectional and limited to clozapine-treated patients.
- Study Age:
- Published in 2022.
- Original Title:
- Early versus late risk factors for deficit and nondeficit schizophrenia.
- Published In:
- Revista de psiquiatria y salud mental, 15(1), 38-46 (2022)
- Authors:
- Alabaf, Setareh, Kirkpatrick, Brian, Chen, Shanquan, Cardinal, Rudolf N, Fernandez-Egea, Emilio
- Database ID:
- RTHC-03661
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Does cannabis affect all schizophrenia symptoms equally?
No. This study found cannabis use was associated with psychotic symptoms (hallucinations, delusions) but not with primary negative symptoms (emotional blunting, social withdrawal).
What does this mean for schizophrenia subtypes?
It suggests schizophrenia with prominent negative symptoms may have different causes (more neurodevelopmental) than schizophrenia driven primarily by psychotic symptoms (more influenced by cannabis and trauma).
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-03661APA
Alabaf, Setareh; Kirkpatrick, Brian; Chen, Shanquan; Cardinal, Rudolf N; Fernandez-Egea, Emilio. (2022). Early versus late risk factors for deficit and nondeficit schizophrenia.. Revista de psiquiatria y salud mental, 15(1), 38-46. https://doi.org/10.1016/j.rpsmen.2022.01.006
MLA
Alabaf, Setareh, et al. "Early versus late risk factors for deficit and nondeficit schizophrenia.." Revista de psiquiatria y salud mental, 2022. https://doi.org/10.1016/j.rpsmen.2022.01.006
RethinkTHC
RethinkTHC Research Database. "Early versus late risk factors for deficit and nondeficit sc..." RTHC-03661. Retrieved from https://rethinkthc.com/research/alabaf-2022-early-versus-late-risk
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.